这是一篇来自已证抗体库的有关人类 DR4的综述,是根据23篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合DR4 抗体。
DR4 同义词: APO2; CD261; DR4; TRAILR-1; TRAILR1

BioLegend
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 s2g
BioLegend DR4抗体(BioLegend, DJR1)被用于被用于流式细胞仪在人类样本上 (图 s2g). Cell Death Dis (2019) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 1b, 1e
BioLegend DR4抗体(Biolegend, 307206)被用于被用于流式细胞仪在人类样本上 (图 1b, 1e). Front Immunol (2019) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 s4d
BioLegend DR4抗体(Biolegend, 307207)被用于被用于流式细胞仪在人类样本上 (图 s4d). Cell (2016) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 st1
BioLegend DR4抗体(BioLegen d, 307206)被用于被用于流式细胞仪在人类样本上 (图 st1). Exp Cell Res (2016) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 4
BioLegend DR4抗体(BioLegend, 307205)被用于被用于流式细胞仪在人类样本上 (图 4). PLoS ONE (2015) ncbi
小鼠 单克隆(DJR1)
  • 免疫印迹; 人类; 1:2000
BioLegend DR4抗体(BioLegend, 307201)被用于被用于免疫印迹在人类样本上浓度为1:2000. PLoS ONE (2014) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类
BioLegend DR4抗体(Biolegend, DJR1)被用于被用于流式细胞仪在人类样本上. Clin Cancer Res (2014) ncbi
赛默飞世尔
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 4c
赛默飞世尔 DR4抗体(eBioscience, 12-6644-41)被用于被用于流式细胞仪在人类样本上 (图 4c). Cell Death Differ (2019) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类; 图 s2
赛默飞世尔 DR4抗体(eBioscience, DJR1)被用于被用于流式细胞仪在人类样本上 (图 s2). BMC Biotechnol (2016) ncbi
小鼠 单克隆(DJR1)
  • 流式细胞仪; 人类
赛默飞世尔 DR4抗体(eBioscience, DJR1)被用于被用于流式细胞仪在人类样本上. J Biol Chem (2013) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 人类; 1:400; 图 1b
艾博抗(上海)贸易有限公司 DR4抗体(Abcam, ab8414)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:400 (图 1b). PLoS ONE (2020) ncbi
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 人类; 1:200; 图 1b
艾博抗(上海)贸易有限公司 DR4抗体(Abcam, ab8416)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 (图 1b). PLoS ONE (2020) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:500; 图 5g
艾博抗(上海)贸易有限公司 DR4抗体(Abcam, ab8414)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 5g). Mol Cancer Res (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:500; 图 5g
艾博抗(上海)贸易有限公司 DR4抗体(Abcam, ab8416)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 5g). Mol Cancer Res (2017) ncbi
圣克鲁斯生物技术
小鼠 单克隆(DR4.1)
  • 流式细胞仪; 人类; 图 3a
圣克鲁斯生物技术 DR4抗体(Santa Cruz, sc-32255)被用于被用于流式细胞仪在人类样本上 (图 3a). Oncotarget (2016) ncbi
小鼠 单克隆(B-9)
  • 免疫细胞化学; 人类; 1:500
圣克鲁斯生物技术 DR4抗体(Santa, B9)被用于被用于免疫细胞化学在人类样本上浓度为1:500. J Biol Chem (2011) ncbi
Enzo Life Sciences
小鼠 单克隆(HS101)
  • 流式细胞仪; 人类; 图 4
Enzo Life Sciences DR4抗体(Enzo, ALX-804-297F-T100)被用于被用于流式细胞仪在人类样本上 (图 4). Oncotarget (2016) ncbi
安迪生物R&D
小鼠 单克隆(69036)
  • 流式细胞仪; 人类; 图 5h
安迪生物R&D DR4抗体(R&D Systems, FAB347P)被用于被用于流式细胞仪在人类样本上 (图 5h). Mol Cancer Res (2017) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(D9S1R)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 DR4抗体(CST, 42533)被用于被用于免疫印迹在人类样本上 (图 2a). Cell Death Dis (2020) ncbi
domestic rabbit 单克隆(D9S1R)
  • 免疫印迹; 人类; 图 s4f
赛信通(上海)生物试剂有限公司 DR4抗体(CST, 42533)被用于被用于免疫印迹在人类样本上 (图 s4f). Cell Death Differ (2019) ncbi
domestic rabbit 单克隆(D9S1R)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 DR4抗体(Cell Signaling Technology, D9S1R)被用于被用于免疫印迹在人类样本上 (图 2a). Sci Rep (2017) ncbi
domestic rabbit 单克隆(D9S1R)
  • 免疫印迹基因敲除验证; 人类; 1:1000; 图 9e
赛信通(上海)生物试剂有限公司 DR4抗体(Cell Signaling, D9S1R)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:1000 (图 9e). Mol Cell Biol (2017) ncbi
domestic rabbit 单克隆(D9S1R)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 DR4抗体(Cell Signaling, 42533)被用于被用于免疫印迹在人类样本上 (图 2a). Int J Biochem Cell Biol (2017) ncbi
贝克曼库尔特实验系统(苏州)有限公司
小鼠 单克隆(2.7A6A3)
  • 流式细胞仪; 人类; 图 1
贝克曼库尔特实验系统(苏州)有限公司 DR4抗体(BD Biosciences, IM2088U)被用于被用于流式细胞仪在人类样本上 (图 1). Cancer Biol Ther (2015) ncbi
小鼠 单克隆(2.7A6A3)
  • 流式细胞仪; 人类; 表 1
贝克曼库尔特实验系统(苏州)有限公司 DR4抗体(Immunotech, 2.7A6A3)被用于被用于流式细胞仪在人类样本上 (表 1). J Transl Med (2014) ncbi
小鼠 单克隆(2.7A6A3)
  • 流式细胞仪; 人类
贝克曼库尔特实验系统(苏州)有限公司 DR4抗体(Beckman Coulter, IM2088U)被用于被用于流式细胞仪在人类样本上. Cell Death Dis (2014) ncbi
ProSci
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2a
ProSci DR4抗体(ProSci, 1139)被用于被用于免疫印迹在人类样本上 (图 2a). EMBO J (2017) ncbi
文章列表
  1. Ding B, Yuan F, Damle P, Litovchick L, Drapkin R, Grossman S. CtBP determines ovarian cancer cell fate through repression of death receptors. Cell Death Dis. 2020;11:286 pubmed 出版商
  2. Jun B, Lee W, Jang J, Jeong S, Chang Y, Lee S, et al. Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection. PLoS ONE. 2020;15:e0227440 pubmed 出版商
  3. Chollat Namy M, Ben Safta Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10:695 pubmed 出版商
  4. Staniek J, Lorenzetti R, Heller B, Janowska I, Schneider P, Unger S, et al. TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes. Front Immunol. 2019;10:951 pubmed 出版商
  5. Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed 出版商
  6. Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735 pubmed 出版商
  7. Lafont E, Kantari Mimoun C, Dráber P, De Miguel D, Hartwig T, Reichert M, et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J. 2017;36:1147-1166 pubmed 出版商
  8. Iurlaro R, Püschel F, León Annicchiarico C, O Connor H, Martin S, Palou Gramón D, et al. Glucose Deprivation Induces ATF4-Mediated Apoptosis through TRAIL Death Receptors. Mol Cell Biol. 2017;37: pubmed 出版商
  9. Dimberg L, Towers C, Behbakht K, Hotz T, Kim J, Fosmire S, et al. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017;15:382-394 pubmed 出版商
  10. Park S, Jwa E, Shin S, Ju E, Park I, Pak J, et al. Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage. Int J Biochem Cell Biol. 2017;83:47-55 pubmed 出版商
  11. Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167:419-432.e16 pubmed 出版商
  12. Wang Z, Yu B, Wang B, Yan J, Feng X, Wang Z, et al. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Oncotarget. 2016;7:47287-47301 pubmed 出版商
  13. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  14. Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, et al. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol. 2016;16:17 pubmed 出版商
  15. De Toni E, Ziesch A, Rizzani A, Török H, Hocke S, Lü S, et al. Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis. Oncotarget. 2016;7:9477-90 pubmed 出版商
  16. Braun F, Mathur R, Sehgal L, Wilkie Grantham R, Chandra J, Berkova Z, et al. Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis. PLoS ONE. 2015;10:e0117994 pubmed 出版商
  17. Gomez Bougie P, Halliez M, Maïga S, Godon C, Kervoëlen C, Pellat Deceunynck C, et al. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biol Ther. 2015;16:60-5 pubmed 出版商
  18. Su Y, Cheng T, Chen C, Chang W, Tsai N, Kung C, et al. Investigation of the caspase-dependent mitochondrial apoptotic pathway in mononuclear cells of patients with systemic Lupus erythematosus. J Transl Med. 2014;12:303 pubmed 出版商
  19. Chandrasekaran S, Marshall J, Messing J, Hsu J, King M. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids. PLoS ONE. 2014;9:e111487 pubmed 出版商
  20. Sullivan E, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, et al. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res. 2014;20:5986-94 pubmed 出版商
  21. Pavet V, Shlyakhtina Y, He T, Ceschin D, Kohonen P, Perala M, et al. Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. Cell Death Dis. 2014;5:e1043 pubmed 出版商
  22. Linderoth E, Pilia G, Mahajan N, Ferby I. Activated Cdc42-associated kinase 1 (Ack1) is required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor recruitment to lipid rafts and induction of cell death. J Biol Chem. 2013;288:32922-31 pubmed 出版商
  23. Cazanave S, Mott J, Bronk S, Werneburg N, Fingas C, Meng X, et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286:39336-48 pubmed 出版商